X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (217) 217
oncology (203) 203
female (181) 181
index medicus (179) 179
breast cancer (140) 140
breast neoplasms - drug therapy (123) 123
middle aged (118) 118
chemotherapy (104) 104
adult (102) 102
aged (100) 100
breast neoplasms - pathology (91) 91
cancer (86) 86
antineoplastic combined chemotherapy protocols - therapeutic use (64) 64
treatment outcome (58) 58
care and treatment (57) 57
metastasis (48) 48
antineoplastic agents - therapeutic use (47) 47
medicine & public health (45) 45
survival (45) 45
disease-free survival (44) 44
aged, 80 and over (42) 42
trastuzumab (42) 42
therapy (38) 38
article (35) 35
antineoplastic combined chemotherapy protocols - adverse effects (34) 34
neoplasm metastasis (34) 34
women (34) 34
antineoplastic agents - adverse effects (33) 33
breast neoplasms - metabolism (33) 33
breast neoplasms - mortality (31) 31
neoplasm staging (31) 31
prognosis (31) 31
research (31) 31
tumors (30) 30
clinical trials (29) 29
cancer therapies (27) 27
patients (27) 27
receptor, erbb-2 - metabolism (26) 26
bevacizumab (25) 25
breast neoplasms - genetics (25) 25
analysis (24) 24
hematology, oncology and palliative medicine (24) 24
paclitaxel (24) 24
trial (24) 24
health aspects (23) 23
postmenopausal women (23) 23
quality of life (23) 23
risk factors (23) 23
abridged index medicus (21) 21
capecitabine (21) 21
metastases (21) 21
metastatic breast cancer (21) 21
risk (21) 21
drug therapy (20) 20
tamoxifen (20) 20
cancer research (19) 19
double-blind (19) 19
efficacy (19) 19
expression (19) 19
patient outcomes (19) 19
breast neoplasms - therapy (18) 18
endocrine therapy (18) 18
male (18) 18
medicine, general & internal (18) 18
oncology, experimental (18) 18
adjuvant chemotherapy (17) 17
breast-cancer (17) 17
chemotherapy, adjuvant (17) 17
endothelial growth-factor (17) 17
neoadjuvant therapy (17) 17
safety (17) 17
animals (16) 16
antibodies, monoclonal, humanized (16) 16
drug administration schedule (16) 16
everolimus (16) 16
usage (16) 16
antibodies, monoclonal, humanized - administration & dosage (15) 15
cancer patients (15) 15
clinical trials as topic (15) 15
erbb-2 protein (15) 15
kaplan-meier estimate (15) 15
prevention (15) 15
antibodies, monoclonal - adverse effects (14) 14
combination (14) 14
epidermal growth factor (14) 14
her2 (14) 14
paclitaxel - administration & dosage (14) 14
receptors, estrogen - metabolism (14) 14
survival analysis (14) 14
survival rate (14) 14
toxicity (14) 14
antibodies, monoclonal - administration & dosage (13) 13
carcinoma (13) 13
double-blind method (13) 13
gene expression (13) 13
letrozole (13) 13
original reports (13) 13
quality-of-life (13) 13
anthracycline (12) 12
antimitotic agents (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 07/2019, Volume 381, Issue 4, pp. 371 - 372
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 22, pp. 2108 - 2121
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 2/2012, Volume 109, Issue 8, pp. 2796 - 2801
Retrospective clinical studies have used immune-based biomarkers, alone or in combination, to predict survival outcomes for women with breast cancer (BC);... 
T lymphocytes | Cytometry | Lymphocytes | Breasts | BREAST CANCER SPECIAL FEATURE | Residual neoplasm | Breast cancer | Leukocytes | Macrophages | Tumors | Cancer | Inflammation | Macrophage | INFILTRATING LYMPHOCYTES | MULTIDISCIPLINARY SCIENCES | VEGF EXPRESSION | macrophage | MICROVESSEL DENSITY | MAMMARY-TUMORS | inflammation | MOUSE MODEL | REGULATORY T-CELLS | TUMOR-ASSOCIATED MACROPHAGES | CARCINOMA | PROGRESSION | ENDOTHELIAL GROWTH-FACTOR | Neoplasm, Residual - pathology | Leukocytes - pathology | Breast Neoplasms - immunology | Humans | Antineoplastic Agents - therapeutic use | Cell Lineage - drug effects | Antigens, CD - metabolism | Leukocytes - immunology | Lymphocyte Activation - immunology | Myeloid Cells - immunology | T-Lymphocytes - drug effects | Biomarkers, Tumor - metabolism | Female | Myeloid Cells - drug effects | Neoadjuvant Therapy | Neoplasm, Residual - immunology | Antineoplastic Agents - pharmacology | T-Lymphocytes - pathology | Cytotoxicity, Immunologic - drug effects | Lymphocytes, Tumor-Infiltrating - drug effects | Breast Neoplasms - drug therapy | Cell Movement - drug effects | Phenotype | Lymphocytes, Tumor-Infiltrating - pathology | Breast Neoplasms - pathology | Lymphocyte Activation - drug effects | Antigens, Differentiation, Myelomonocytic - metabolism | Leukocytes - drug effects | T-Lymphocytes - immunology | Myeloid Cells - pathology | Lymphocytes, Tumor-Infiltrating - immunology | Physiological aspects | Development and progression | Health aspects | Biological Sciences
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 2, pp. 175 - 176
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2016, Volume 375, Issue 1, pp. 23 - 34
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 20, pp. 1925 - 1936
Journal Article
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 09/2017, Volume 23, Issue 17, pp. 5218 - 5224
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2018, Volume 379, Issue 8, pp. 753 - 763
Journal Article